title: Biomarkers of disease and treatment in murine and cynomolgus models of chronic asthma.
abstract: BACKGROUND
  Biomarkers facilitate early detection of disease and measurement of therapeutic efficacy, both at clinical and experimental levels. Recent advances in analytics and disease models allow comprehensive screening for biomarkers in complex diseases, such as asthma, that was previously not feasible.
  
  
  OBJECTIVE
  Using murine and nonhuman primate (NHP) models of asthma, identify biomarkers associated with early and chronic stages of asthma and responses to steroid treatment.
  
  
  METHODS
  The total protein content from thymic stromal lymphopoietin transgenic (TSLP Tg) mouse BAL fluid was ascertained by shotgun proteomics analysis. A subset of these potential markers was further analyzed in BAL fluid, BAL cell mRNA, and lung tissue mRNA during the stages of asthma and following corticosteroid treatment. Validation was conducted in murine and NHP models of allergic asthma.
  
  
  RESULTS
  Over 40 proteins were increased in the BAL fluid of TSLP Tg mice that were also detected by qRT-PCR in lung tissue and BAL cells, as well as in OVA-sensitive mice and house dust mite-sensitive NHP. Previously undescribed as asthma biomarkers, KLK1, Reg3γ, ITLN2, and LTF were modulated in asthmatic mice, and Clca3, Chi3l4 (YM2), and Ear11 were the first lung biomarkers to increase during disease and the last biomarkers to decline in response to therapy. In contrast, GP-39, LCN2, sICAM-1, YM1, Epx, Mmp12, and Klk1 were good indicators of early therapeutic intervention. In NHP, AMCase, sICAM-1, CLCA1, and GP-39 were reduced upon treatment with corticosteroids.
  
  
  CONCLUSIONS
  These results significantly advance our understanding of the biomarkers present in various tissue compartments in animal models of asthma, including those induced early during asthma and modulated with therapeutic intervention, and show that BAL cells (or their surrogate, induced sputum cells) are a viable choice for biomarker examination.
authors: Merck Research Laboratories (formerly Schering-Plough Biopharma) Palo Alto, California USA.
authors: Jennifer
authors: J
authors: Louten
authors: Jeanine D
authors: JD
authors: Mattson
authors: Maria-Christina
authors: MC
authors: Malinao
authors: Ying
authors: Y
authors: Li
authors: Claire
authors: C
authors: Emson
authors: Felix
authors: F
authors: Vega
authors: Robert L
authors: RL
authors: Wardle
authors: Michael R
authors: MR
authors: Van Scott
authors: Robert B
authors: RB
authors: Fick
authors: Terrill K
authors: TK
authors: McClanahan
authors: Rene
authors: R
authors: de Waal Malefyt
authors: Maribel
authors: M
authors: Beaumont